Abbott strengthens left atrial appendage closure leadership with u.s. availability of amplatzer™ steerable delivery sheath for the company's amulet™ device

First and only steerable delivery system designed to help seal the left atrial appendage (laa) in people with atrial fibrillation who are at an increased risk of stroke now available in the u.s., abbott's steerable sheath offers precise and flexible placement when used with the company's amplatzer amulet laa occluder abbott park, ill., april 28, 2022 /prnewswire/ -- abbott (nyse: abt) today announced u.s. availability of its amplatzer™ steerable delivery sheath, which is used with the company's amplatzer amulet™ left atrial appendage (laa) occluder to treat people with atrial fibrillation (afib) who are at risk of ischemic stroke.
ABT Ratings Summary
ABT Quant Ranking